Obicetrapib
Cardiovascular Outcomes
Phase 3Active (PREVAIL trial)
Key Facts
About NewAmsterdam Pharma
NewAmsterdam Pharma's mission is to develop innovative oral therapies for cardiovascular and lipid-related diseases, targeting the large population of patients failing to achieve LDL-C goals. Its core achievement is the late-stage development of obicetrapib, a CETP inhibitor with compelling Phase 3 efficacy and safety data, supported by over $1.2 billion in total capital raised. The company's strategy involves securing regulatory approval, preparing for a U.S. launch, and leveraging ex-U.S. partnerships like the one with Menarini Group to maximize global commercial potential.
View full company profileTherapeutic Areas
Other Cardiovascular Outcomes Drugs
| Drug | Company | Phase |
|---|---|---|
| Obicetrapib (TA-8995) | NewAmsterdam Pharma Company | Phase 3 |